Hereditary Angioedema (HAE)

Rare Disease·MeSH: Angioedemas, Hereditary

Prevalence

5.0 / 100K

10 drugs in development·7 companies·17 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
DAWNZERA™ (donidalorsen)	IONIS PHARMACEUTICALS INC (IONS)
ekterly	KalVista Pharmaceuticals, Inc. (KALV)

Phase 3(3)

Drug	Company
deucrictibant	Pharvaris N.V. (PHVS)
navenibart	Astria Therapeutics, Inc. (ATXS)
otl-105	Orchard Therapeutics plc (ORTX)

Phase 2(1)

Drug	Company
donidalorsen	IONIS PHARMACEUTICALS INC (IONS)

Unknown(4)

Drug	Company
icatibant	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
icatibant	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
lanadelumab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
lanadelumab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 10 drugs in development for Hereditary Angioedema (HAE) across 7 companies.

There are 17 clinical trials targeting Hereditary Angioedema (HAE) tracked by BioSniper.

The estimated prevalence of Hereditary Angioedema (HAE) is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.